Research and Markets (http://www.researchandmarkets.com/research/4bbc14/macular_oedema_d) has announced the addition of GlobalData 's new report "Macular Oedema - Drug Pipeline Analysis and Market Forecasts to 2016" to their offering.
“Macular Oedema - Drug Pipeline Analysis and Market Forecasts to 2016”
Macular Oedema - Drug Pipeline Analysis and Market Forecasts to 2016
GlobalData, the industry analysis specialists new report, Macular Oedema - Drug Pipeline Analysis and Market Forecasts to 2016 is an essential source of information and analysis on the global macular oedema market. The report identifies the key trends shaping and driving the market, and provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global macular oedema sector.
The Macular Oedema Market is Forecast to Show Modest Growth to 2016
GlobalData valued the global macular oedema market at $3.8 billion in 2009. It is expected to grow to $5.3 billion with a Compound Annual Growth Rate (CAGR) of 5% by 2016. This growth is primarily attributed to the increased prevalence and incidence rates of diabetes across the world. Macular oedema is a slowly progressing disease and diabetes is cited as the main cause of such ocular diseases. The growth will be supported by the increased competition between the traditionally used off label products and the newly approved drugs and is expected to continue in the future.
Global Macular Oedema Market Forecast 2009-2016
Macular Oedema Market Set To Witness Intense Competition Between Off Label and Recently Approved Products
GlobalData has found the current competition in the macular oedema market is set to become more intense due to the increased usage of off label products by physicians. This is the result of the lack of an approved drug in the market, thereby forcing physicians to use off label drugs to treat patients. Unlike the other back-of-the-eye disease markets where there are approved drugs with which new entrants have to compete; this market will have no approved drugs available until late 2009. The only approved product, Ozurdex, is relatively new in the market and the competition scenario in this case is reversed as the newly approved products have to compete with products that have been used off label for many years. This is likely to intensify the market competition in the next few years.
Scope
The scope of the report includes: